Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,726 matching trials from the live ClinicalTrials.gov search.
Conditions
Hepatocellular Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma, Metastasis, Neoplasm
Interventions
Carfilzomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
nicotine, varenicline, placebo
Drug · Other
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
PHY906, capecitabine
Drug
Lead sponsor
PhytoCeutica
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
4
States / cities
Duarte, California • Stanford, California • New Haven, Connecticut + 1 more
Conditions
Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Interventions
Pembrolizumab Monotherapy, Ramucirumab, Paclitaxel
Drug
Lead sponsor
Harry H Yoon
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Milwaukee, Wisconsin
Conditions
Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
Interventions
HFB200603, Tislelizumab
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Philadelphia, Pennsylvania • Fairfax, Virginia
Conditions
Hepatocellular Carcinoma
Interventions
Enzalutamide, Enzalutamide with Sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
5
States / cities
San Francisco, California • St Louis, Missouri • Buffalo, New York + 2 more
Conditions
Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer
Interventions
TNO155, Spartalizumab, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Neoplasms, Liver Neoplasms
Interventions
Yttrium-90 Radioactive Resin Microspheres
Device
Lead sponsor
Tony Reid, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Conditions
Colorectal Cancer
Interventions
cetuximab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma
Interventions
Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

EXERCISING TOGETHER for Couples Coping With Cancer

NCT03630354
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Colorectal Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Exercise Intervention (supervised), Exercise Intervention (unsupervised), Informational Intervention, Questionnaire Administration
Behavioral · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma
Interventions
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • Cleveland, Ohio + 1 more
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C, flat dose 40 mg, Mitomycin C, weight-based dose 12.5 mg/m2
Drug
Lead sponsor
Prakash Pandalai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Lexington, Kentucky • Burlington, Vermont
Conditions
Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
Interventions
Everolimus 10 mg, Octreotide Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Conditions
Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer, Cancer of Gallbladder
Interventions
Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin, Carboplatin, Capecitabine, 5FU, Liver transplantation
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Malignant Digestive System Neoplasm, Rectal Carcinoma, Small Intestinal Carcinoma
Interventions
PAGODA algorithm, Oxaliplatin, Folinic Acid, Fluorouracil
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
360
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 268 more
Conditions
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
Interventions
GQ1001
Drug
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma, Mesothelioma, Neuroendocrine Tumors, Squamous Cell Cancer, Merkel Cell Carcinoma, Mismatch Repair Deficiency, Microsatellite Instability
Interventions
Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination
Biological · Drug
Lead sponsor
Udai Kammula
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
Interventions
nab-Paclitaxel, Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
107
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
Conditions
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Interventions
DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Esophageal Cancer, Stomach Cancer
Interventions
KD019
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more